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Background: Bleeding complications in cardiac surgery may lead to increased morbidity and mortality. Traditional
blood coagulation tests are not always suitable to detect rapid changes in the patient's coagulation status.
Point-of-care instruments such as the TEG (thromboelastograph) and RoTEM (thromboelastometer) have been
shown to be useful as a guide for the clinician in the choice of blood products and they may lead to a reduction
in the need for blood transfusion, contributing to better patient blood management.
Methods: The purpose of this study was to evaluate the ability of the TEG, RoTEM and Sonoclot instruments to
detect changes in hemostasis in elective cardiac surgery with cardiopulmonary bypass and to investigate possible
correlations between variables from these three instruments and routine hematological coagulation tests. Blood
samples from thirty-five adult patients were drawn before and after surgery and analyzed in TEG, RoTEM, Sonoclot
and routine coagulation tests. Data were compared using repeated measures analysis of variance and Pearson's
test for linear correlation.
Results: We found significant changes for all TEG variables after surgery, for three of the RoTEM variables, and for
one variable from the Sonoclot. There were significant correlations postoperatively between plasma fibrinogen
levels and variables from the three instruments.
Conclusions: TEG and RoTEM may be used to detect changes in hemostasis following cardiac surgery with CPB.
Sonoclot seems to be less suitable to detect such changes. Variables from the three instruments correlated with
plasma fibrinogen and could be used to monitor treatment with fibrinogen concentrate.
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Excessive bleeding in cardiac surgery occurs in as much as
20% of patients. It is associated with increased morbidity
and mortality, mainly caused by need for reexploration
and transfusion of blood products [1-6]. In 15-50% of the
patients undergoing reexploration, a surgical cause of
bleeding cannot be found [7,8] and it is assumed to be of
microvascular origin. The pathogenesis of microvascular
bleeding in cardiac surgery is multifactorial and may be
related to changes in the hemostatic system associated* Correspondence: aurora.espinosa@stolav.no
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unless otherwise stated.with increased age, preoperative medication with platelet
and/or coagulation inhibitors, and transient platelet dys-
function associated with cardiopulmonary bypass (CPB)
[6-12]. The use of CPB induces a systemic inflammatory
response with activation of both the coagulation and
fibrinolytic systems, followed by coagulopathy caused
by factor consumption and transiently reduced platelet
count and function [13,14].
To date, there is no “gold standard” test for the assess-
ment of microvascular bleeding in cardiac surgery. Peri-
operative monitoring of the hemostatic process by a
combination of conventional coagulation tests may be
helpful in diagnosing possible causes of bleeding [15,16].
However, the value of these tests has been questioned,al Ltd. This is an Open Access article distributed under the terms of the Creative
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in plasma and do not add information about platelet
function or the contribution of the cellular components
[17,18].
In the last decade, viscoelastic point-of-care (POC)
coagulation instruments such as the thromboelasto-
graph (TEG), the thromboelastometer (RoTEM) and
the Sonoclot have been increasingly used in clinical
practice for perioperative monitoring of excessive bleeding
in cardiac surgery [18-20]. These POC instruments pro-
vide information about the quality and dynamics of the
clot, are relatively simple to operate and can be used
close to the patient. The results are usually ready for
interpretation within 15–30 minutes. Guidelines for
interpretation and use of POC instruments in the man-
agement of perioperative coagulopathy and transfusion
algorithms have been developed [21]. These instruments
may be helpful as a guide for transfusion therapy and to
decide whether to reexplore a patient or not [17-19,22].
Although with some differences, these instruments are
based on similar principles and provide output in the
form of a similar graphical tracing. However, it is still
not clear whether TEG, RoTEM and Sonoclot provide
identical information. The performance of different POC
instruments in cardiac surgery has been evaluated in
previous studies [22-24] but, to our knowledge, TEG,
RoTEM and Sonoclot instruments have not previously
been directly compared in the same group of cardiac
surgery patients.
The primary objective of this study was to evaluate the
comparability of the results obtained from the TEG,
RoTEM and Sonoclot instruments by assessing their
ability to detect changes in hemostasis caused by CPB.
In addition, we also investigated whether variables from
the TEG, RoTEM and Sonoclot analyses were correlated
to results from a selection of conventional coagulation
tests.
Methods
Study design and patients
This study was a prospective observational study. Thirty-
five patients (22 men and 13 women) scheduled for elect-
ive cardiac surgery with the use of CPB were included
after giving written informed consent. All patients were
treated with aspirin until the day before surgery. Patients
who had been treated with clopidogrel within five days
prior to surgery were not considered eligible to the study.
Group assignment and procedures
Patients with unstable angina received low molecular
weight heparin preoperatively. Tranexamic acid 30 mg/kg
was given to all patients prior to CPB according to depart-
mental routines. Before CPB, the patients received heparin
300 U/kg (Leo, Copenhagen, Denmark) through a centralvenous line to achieve a kaolin activated clotting time
(ACT) (Medtronic Blood Management, Parker, CO, USA)
of > 480 seconds. Additional heparin was given when
needed to keep the ACT above the target. During CPB,
the ACT was monitored every 20 minutes. The perfusion
circuit was primed with 1800 mL of Ringer’s acetate
solution with 7500 U of heparin. A membrane oxygenator
without heparin coating was used.
Cold antegrade and/or retrograde blood or crystalloid
cardioplegia and moderate hypothermia to 34°C were
used during CPB. Cardiotomy suction was used while
the patients were fully anticoagulated, and the blood was
returned to the patients without centrifugation. The
patients were warmed to a rectal temperature of at least
36°C before termination of CPB. After CPB, protamine
sulphate was given to achieve an ACT within 10% of the
baseline value. Blood remaining in the CPB circuit was
collected and transfused to the patient. Postoperatively,
transfusions of packed red cells were given when the
hemoglobin concentration was < 8.5 – 9.0 g/dL. Persistent
postoperative bleeding of more than 200 mL/h was treated
with infusions of desmopressin, fresh frozen plasma and/
or platelet concentrates, or reexploration at the discretion
of the attending clinician.
To identify possible hemostatic changes caused by CPB
in the TEG, RoTEM, Sonoclot and conventional coagula-
tion tests, blood samples were collected at three different
time points: preoperatively (immediately before anesthesia
induction), and at 1 and 24 hours postoperatively. Blood
samples for TEG and RoTEM analyses were drawn into
a tube containing citrate and analyzed within 1 hour,
after recalcification with 20 μL CaCl2. Blood samples
for Sonoclot analysis were drawn into syringes without
additives and transferred to the Sonoclot cuvette for
immediate analysis. All the tests for the TEG, RoTEM
and Sonoclot were performed by the same investigator
(AE), and all Sonoclot tracings were interpreted by a
single investigator (HP). The operating principles of the
TEG (Haemoscope Corp., Niles, IL, USA), RoTEM
(Pentapharm GmbH, Munich, Germany) and the Sonoclot
analyzer (Sienco Inc., Arvada, CO, USA) are described in
detail by Ganter and Hofer [17]. Nomenclature and explan-
ation for the different TEG, RoTEM and Sonoclot variables,
as well as the reference values are given in Table 1.
Citrate-anticoagulated samples were analyzed consecu-
tively for hemoglobin concentration, platelet counts, inter-
national normalized ratio (INR), activated thromboplastin
time (aPTT), fibrinogen, d-dimer and antithrombin by
standard methods at the Department of Medical Biochem-
istry at St. Olav University Hospital.
Statistical analysis
Data are given as frequencies or means with standard
deviation (SD). For the statistical analysis of the RoTEM
Table 1 Nomenclature, variable definitions and reference ranges of the TEG, RoTEM and Sonoclot instruments
TEG RoTEM Sonoclot
Clot time R (Reaction time) CT (Clotting time) -
Time to 2 mm amplitude (4–8 min.) -EXTEM CT (42–74 sec)*
-INTEM CT (137–246 sec)
Clot kinetics K (kinetics) CFT (Clot formation time) -
Time from 2 to 20 mm clot firmness (1–4 min.) -EXTEM CFT (46–148 sec)
-INTEM CFT (40–100 sec)
Clot kinetics Alpha angle Alpha angle -
Alpha angle (53–67 deg) -EXTEM angle (63–81 deg)
-INTEM angle (71–82 deg)
Clot strength MA (Maximum amplitude) MCF (Maximum Clot Firmness) -
-EXTEM MCF ( 49–71 mm)
(55–73 mm) -INTEM MCF (52–72 mm)
-FIBTEM MCF (9–25 mm).
Clot elasticity G (4.6-10.9 dynes/cm2) - -
Time until the beginning of fibrin formation - - Son Act (85–145 sec)
Rate of fibrin formation - - Clot Rate R1 (15–45 clot signal units/min)
Completion of fibrin formation - - Peak (mm)
Index of fibrinogen conversion to fibrin - - Time to Peak (540–600 sec)
Platelet-induced clot retraction - - R3 (>2 mm/min)
*EXTEM reagent contains tissue factor, INTEM reagent contains ellagic acid, FIBTEM reagent contains platelet inhibitor.
Table 2 Patient demographics and data on surgical
procedures (n = 35)
Age (years) 62.8 (10.3)*
Gender (male/female) 22/13
Weight (kg) 82.7 (13.4)*
Preoperative blood hemoglobin concentration (g/dL) 13.7 (1.4)*
Preoperative LMWH (yes/no) 7/28




Combined CABG and valve surgery 3
Surgical time (min) 156 (46)*
Cardiopulmonary bypass time (min) 82 (36)*
Aortic cross-clamp time (min) 52 (29)*
Red cell transfusion (yes/no) 15/20
Fresh frozen plasma (yes/no) 8/27
Platelet transfusion (yes/no) 3/32
Desmopressin 30 μg/kg (yes/no) 6/29
*Values expressed as mean (SD).
Gender, preoperative LMWH, operation type, red cell transfusion, fresh frozen
plasma transfusion, platelet transfusion and treatment with desmopressin are
given as total number of patients in each category.
CABG = coronary artery bypass grafting, EuroSCORE = The European System for
Cardiac Operative Risk Evaluation, LMWH = low molecular weight heparin.
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used to ensure comparability because the TEG and
Sonoclot instruments do not give early values. Repeated
measures analysis of variance (ANOVA) was used for
analysis of changes in continuous variables by time. If
necessary to obtain a good model fit, logarithmic or
rank transformation was performed. p-values < 0.05 were
considered statistically significant in the ANOVA analysis.
Linear correlations were evaluated by Pearson’s R. To
correct for correlations calculated at multiple time points,
correlations with p-values < 0.01 were considered sig-
nificant. Statistical analysis was performed using the
program SPSS for Windows, version 16.0 (SPSS Inc.
Chicago, IL, USA).
Protocol approval and patient consent
This was a prospective observational study, approved
by the Regional Committee for Medical Research Ethics,
Central Norway. All patients who were asked to partici-
pate in the study consented.
Results and discussion
Patient demographics, medical data and data on surgical
procedures are presented in Table 2.
All the analyzed conventional coagulation tests differed
significantly with time (Table 3). There were significant
changes with time for the TEG variables R (reaction time),
K (clot kinetics), alpha (clot strengthening), MA (clot
Table 3 Conventional coagulation tests at the three time
points (n = 35)




Hemoglobin (g/dL) 13.1 (1.5) 10.5 (1.4)** 10.2 (1.4)**
Platelet counta (×10e9/L) 226 (49) 182 (58)** 165 (56)**
Fibrinogen (g/L)b 3.4 (0.8) 2.4 (0.5)** 3.3 (0.6)
d-dimerb (mg/L) 0.6 (0.6) 0.8 (0.9)** 0.4 (0.4)**
Antithrombin (%) 92 (10) 68 (13)** 75 (15)**
INRa 1.1 (0.1) 1.2 (0.1)** 1.3 (0.1)**
aPTT ( seconds) 28 (2.2) 31 (11.5)* 27 (2.6)*
Values are expressed as mean (SD).
INR - International Normalized Ratio, aPTT - activated thromboplastin time.
aLogarithmic transformation.
bRank transformation.
*p <0.05 compared to baseline.
**p < 0.001 compared to baseline.
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preoperative results and the results recorded 1 hour after
surgery (Table 4). MA and G were also significantly differ-
ent from baseline 24 hours postoperatively. The RoTEM
variables INTEM CT (clotting time), INTEM CFT (clot
kinetics) and FIBTEM MCF (clot strength) changed
significantly with time. For the Sonoclot, only Son ACT
values (time until fibrin formation) differed significantly
with time.
Correlations between the conventional coagulation tests
and POC variables are given in Table 5. TEG MA (clot
strength) and RoTEM MCF (clot strength) correlated with
fibrinogen at baseline. Even though both TEG alpha (clot
strengthening) and TEG G (clot elasticity) were correlatedTable 4 TEG, RoTEM and Sonoclot variables at the three
time points (n = 35)





TEG Ra (min) 8 (2.1) 10 (2.6)* 8 (2.1)
TEG Ka (min) 2 (0.6) 3 (0.7)** 2 (0.5)
TEG alfa (deg) 61 (6.1) 56 (7.5)** 63 (5.6)
TEG MA (mm) 63 (4.3) 58 (4.9)** 61 (6.1)*
TEG Ga (dyn/sec) 9 (1.7) 7 (1.4)** 8 (2.1)*
RoTEM
INTEM CTa (sec) 165 (28.8) 179 (25.6)* 153 (22.5)
INTEM CFT (sec) 79 (32.4) 84 (23.0) 104 (36.2)**
FIBTEM MCFa (mm) 15 (4.3) 12 (3.4)** 16 (9.4)
Sonoclot
SonACTa (sec) 167 (33) 221 (99)* 165 (23)
Values are expressed as mean (SD). For variable definitions, see Table 1.
aLogarithmic transformation.
*p <0.05 compared to baseline.
**p < 0.001 compared to baseline.to fibrinogen 1 and 24 hrs postoperatively and TEG K
(clot kinetics) was correlated to fibrinogen 24 hrs post-
operatively, TEG MA (clot strength) was the only TEG
variable that correlated with fibrinogen at all time-
points. The RoTEM MCF (clot strength) variables and
the Sonoclot Clot Rate (rate of fibrin formation) also
correlated to fibrinogen at all time-points.
Platelet counts correlated with TEG MA (clot strength)
24 hrs postoperatively, and two different RoTEM MCF
variables (clot strength) correlated with platelet counts
either 1 hr or 24 hrs postoperatively. The only correlations
with aPTT were with the Sonoclot variables Son ACT
(time until fibrin formation) and Clot Rate (rate of fibrin
formation) at 1 and 24 hrs postoperatively. None of the
POC variables correlated with INR.
Four patients needed a surgical reexploration, due to
persistent postoperative bleeding (total bleeding 800–
2690 mL). These patients were transfused with red cell
concentrates (6–10 units), platelet concentrates (0–3 units)
and FFP (3–6 units). Two of these patients received an
additional dose of tranexamic acid postoperatively. The
decision of giving tranexamic acid postoperatively was
empirical, as the results of the POC instruments were
not available for the attending physician. None of the
bleeding patients had abnormal baseline values for the
TEG, RoTEM or for the coagulation tests. Preoperative
Sonoclot Son Act (time until fibrin formation) results
were abnormal in three of these patients. However,
pathological Son Act results were found in the majority
of the patients preoperatively. Only one patient showed
pronouncedly reduced RoTEM FIBTEM MCF (maximal
clot firmness), plasma fibrinogen and TEG alpha (clot
strengthening) values in the early postoperative period.
As expected, all the conventional coagulation tests
showed significant changes following cardiac surgery. This
was mirrored in changes in all the TEG variables, some
of the RoTEM variables, and only one of the Sonoclot
variables. The changes pointed towards a more hypo-
coagulable state, consistent with dilutional coagulopathy
and consumption of platelets and coagulation factors
occurring during CPB [7,8]. In most patients, the changes
reversed to baseline values within 24 hours after surgery.
In contrast to other studies [9,12], we did not observe
increased fibrinolysis, which may be explained by the
routine use of a prophylactic antifibrinolytic agent.
Several previous studies [22,25-28] do not support
the routine use of POC instruments prior to surgery to
predict the need for transfusion, due to the high number
of false positive and false negative results obtained.
However, rapid assessment of the cause of bleeding if it
ensues in the postoperative period is essential to provide
adequate treatment to the patient. Alterations in coagula-
tion usually occur during CPB, mainly due to hemodilution
and platelet activation caused by the contact with plastic
Table 5 Correlations between conventional coagulation tests and POC variables (n = 35)
Coagulation
test
1 h postoperatively 24 h postoperatively
POC variable p-value R value p-value R value
Fibrinogen
TEG
TEG K 0.13 - 0.42 0.002 - 0.52
TEG alpha 0.004 0.48** 0.001 0.53**
TEG MA* < 0.0005 0.76** < 0.0005 0.63**
TEG G < 0.0005 0.78** < 0.0005 0.67**
RoTEM
EXTEM MCF* < 0.0005 0.71** 0.001 0.58**
INTEM MCF* 0.001 0.53** < 0.0005 0.63**
FIBTEM MCF* < 0.0005 0.79** 0.003 0.50**
Sonoclot
Clot Rate* 0.002 0.53** 0.008 0.47**
Platelet count
TEG
TEG MA 0.67 0.08 0.009 0.44**
RoTEM
EXTEM MCF < 0.001 0.53** 0.04 0.36
INTEM MCF 0.04 0.36 0.002 0.52
aPTT
Sonoclot
Son ACT <0.0005 0.86** 0.001 0.58**
Clot Rate <0.0005 - 0.67** 0.007 - 0.48**
For variable definitions, see Table 1.
*Statistically significant correlation preoperatively.
**P-values < 0.01 were considered statistically significant.
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sensitive enough to indicate such alterations in hemostasis
in a timely fashion, and the data from 1 hr postoperatively
may be the most relevant when comparing the instruments.
In that regard, a variant of the TEG analysis, Rapid TEG,
where tissue factor is added to kaolin for activation of the
extrinsic pathway has shown promising results. Several
studies have demonstrated that Rapid TEG is useful as the
results are available in about 20 minutes, correlate well with
conventional coagulation tests, and may be used to predict
transfusion of red cells, plasma and platelets [29,30].
From our study, TEG seemed to be the more sensitive
of the POC instruments and the Sonoclot was the least
sensitive. None of our patients had markedly abnormal
hemostasis and we cannot exclude that the instruments
would have given more comparable results in patients
with severe hemostatic disturbances.
Previous comparative studies to assess the interchange-
ability between TEG and RoTEM have been reported
[24,31]. Even if TEG and RoTEM are very similar instru-
ments, there are some differences between them. The
RoTEM instrument analyses each parameter in a separatechannel while in the TEG, all the parameters are analyzed
simultaneously. In the TEG, the cup oscillates around the
metal pin, whereas the pin moves around the cup in the
RoTEM, conferring more stability against vibrations. The
TEG uses kaolin and the RoTEM uses tissue factor
(EXTEM) or the contact activator ellagic acid (INTEM) as
activator of the coagulation process. The different plastic
composition of the reaction cups has been pointed out as
a possible additional factor for the lack of interchangeabil-
ity between the two instruments [17]. All these differences
may explain the divergent results obtained from the two
instruments in our study and reported by other authors.
From our study, it seems that all three POC instruments
may be equally useful to quantify changes in fibrinogen.
The correlations found between various POC variables
and fibrinogen concentrations are consistent with previ-
ous studies [20,32-34]. The importance of fibrinogen in
promoting sufficient coagulation and hemostasis and as
a contributor to the clot strength has lately been under-
scored [17]. Reduced fibrinogen levels during CPB identify
patients at risk for post-operative bleeding and high trans-
fusion requirements [13].
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variable R (reaction time), the RoTEM CT (clotting time)
or the Sonoclot Son ACT (time until fibrin formation),
even if these three parameters all measure the time to the
first fibrin formation. The reason for the discrepancy for
TEG R might be the different activators used; kaolin for
TEG and tissue factor for INR. For the other fibrin time
measures, the reasons for the discrepancies are unknown.
We found that the Sonoclot variables Son ACT and Clot
rate (rate of fibrin formation) correlated significantly
with aPTT. This is as expected, as aPTT is usually pro-
longed in hypocoagulable states, where a low Clot Rate
can be found.
Preoperative platelet counts were within normal ranges
in all the patients. None of the POC tests showed correla-
tions with platelet counts at both time points in the
postoperative period. The explanation may be that the
POC instruments rather assess platelet function than
platelet counts even if they may also indicate when platelet
counts are too low to provide adequate hemostasis. From
this point of view, the POC instruments may be more
clinically useful than standard platelet counts.
Even if the TEG seemed to be more sensitive to detect
hemostatic changes than the two other POC instruments,
its use still carries potential problems. The references for
the manufacturer’s proposed normal values for the TEG
values are very limited and not well validated [34,35].
The manufacturer’s technical manual does not contain
information about factors that may influence the results,
such as gender, age or underlying medical conditions. In
one study in 118 healthy blood donors [35] the authors
found that 18.6% of the donors had at least one abnormal
TEG parameter according to the manufacturer’s reference
values, with the greatest differences involving the R
(reaction time), alpha (clot strengthening) and MA (clot
strength) parameters, even if none of the volunteers
had abnormal routine coagulation assays. The authors
recommended that each institution should determine
its own reference values before adopting TEG. Concerns
regarding blood sample stability and storage conditions
have also been raised [17].
Laboratories should establish standardized procedures
to minimize variability. To solve the mentioned problems
the International TEG-RoTEM Working Group has been
created to try to standardize TEG and RoTEM and to
establish protocols to ensure accurate results [36]. Until
better standardization is possible and the knowledge
about factors influencing the results is increased, the
routine coagulation tests will have to remain the gold
standard for assessment of many aspects of hemostasis.
The main limitation of this study is the small number
of patients. In addition, there was some missing data for
the RoTEM analysis, caused by short-time supplier
problems (n = 1-4). However, our results are consistentwith previous findings from studies with separate evalu-
ation of the TEG, RoTEM and Sonoclot instruments in
cardiac surgery. Our study was not designed to study
clinical outcomes in relation to the POC tests, which
would require a much larger patient population.
Conclusions
In conclusion, TEG and RoTEM can be used to detect
postoperative hemostatic changes following cardiac surgery,
whereas the Sonoclot seems to be less suitable, at least
in patients without grave hemostatic changes. Variables
from TEG, RoTEM and Sonoclot may be useful to monitor
fibrinogen levels. Further studies are necessary to establish
adequate reference values for different patient groups and
to standardize these assays to achieve reliable results.
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